Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival
暂无分享,去创建一个
O. Delattre | F. Tirode | P. Delépine | T. Montier | D. Heymann | K. Laud | F. Redini | L. Geffroy | F. Lamoureux | G. Picarda
[1] S. de Jong,et al. TRAIL receptor signalling and modulation: Are we on the right TRAIL? , 2009, Cancer treatment reviews.
[2] F. Kruyt. TRAIL and cancer therapy. , 2008, Cancer letters.
[3] G. Longton,et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. , 2008, The Journal of clinical investigation.
[4] R. Plummer,et al. Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers , 2007, Clinical Cancer Research.
[5] B. Pitard,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.
[6] N. Athanasou,et al. Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma , 2007, British Journal of Cancer.
[7] J. Eberle,et al. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4 , 2007, Oncogene.
[8] A. Tolcher,et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] F. Gouin,et al. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies , 2007, Expert review of anticancer therapy.
[10] P. Picci. Osteosarcoma (Osteogenic sarcoma) , 2007, Orphanet journal of rare diseases.
[11] P. Marini. Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2. , 2006, Current opinion in molecular therapeutics.
[12] E. Steliarova-Foucher,et al. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. , 2006, European journal of cancer.
[13] I. Holen,et al. Role of osteoprotegerin (OPG) in cancer. , 2006, Clinical science.
[14] M. Heymann,et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice , 2005, Cancer.
[15] B. Fang,et al. Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.
[16] Karen Billeci,et al. Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling* , 2005, Journal of Biological Chemistry.
[17] C. Thiele,et al. Interferon γ Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis–Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing’s Sarcoma , 2004, Cancer Research.
[18] J. Chirgwin,et al. Tumor-bone cellular interactions in skeletal metastases. , 2004, Journal of musculoskeletal & neuronal interactions.
[19] D. Lawrence,et al. Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival , 2004, Cancer Research.
[20] Marc Nasoff,et al. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. , 2004, Cancer cell.
[21] S. Shankar,et al. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. , 2004, International journal of oncology.
[22] Wafik S El-Deiry,et al. TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.
[23] Tomoyuki Saito,et al. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. , 2002, Cancer letters.
[24] L. Shultz,et al. Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma. , 2002, In vivo.
[25] A. Evdokiou,et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosis , 2002, International journal of cancer.
[26] J. Goldblum,et al. Expression of Fli-1, a Nuclear Transcription Factor, Distinguishes Vascular Neoplasms From Potential Mimics , 2001, The American journal of surgical pathology.
[27] O. Delattre,et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression , 2001, Oncogene.
[28] C. Niemeyer,et al. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis , 2001, Cell Death and Differentiation.
[29] S. S. Strom,et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.
[30] N. Mitsiades,et al. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. , 2001, Cancer research.
[31] C. Férec,et al. Cation substitution in cationic phosphonolipids: a new concept to improve transfection activity and decrease cellular toxicity. , 2000, Journal of medicinal chemistry.
[32] P. Lollini,et al. Murine model for skeletal metastases of Ewing's sarcoma , 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[33] A. Craft,et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] C. Férec,et al. Systemic administration of cationic phosphonolipids/DNA complexes and the relationship between formulation and lung transfection efficiency. , 2000, Biochimica et biophysica acta.
[35] D. Lawrence,et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.
[36] H. Jürgens,et al. Deskriptive Epidemiologie der Ewing-Tumoren - Analysen der deutschen Patienten von (EI) CESS 1980-1997* , 1999 .
[37] M. Cohen,et al. Visual presentation of the staging of pediatric solid tumors. , 1996, Radiographics : a review publication of the Radiological Society of North America, Inc.
[38] C. Denny,et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. Santamaría,et al. The neuroectodermal tumor of bone , 1984, The American journal of surgical pathology.
[40] B. Klein,et al. Studies of bone and soft‐tissue tumours induced in rats with radioactive cerium chloride , 1977, International journal of cancer.
[41] F. Graham,et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.
[42] J. Ewing. Diffuse endothelioma of bone , 1972 .
[43] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[44] D. Heymann,et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. , 2006, International journal of oncology.
[45] A. Evdokiou,et al. Death to the bad guys: Targeting cancer via Apo2L/TRAIL , 2005, Apoptosis.
[46] N. Liabakk,et al. Monoclonal antibodies against TRAIL. , 2004, Vitamins and hormones.
[47] 中谷 文彦. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein , 2004 .
[48] M. Urioste,et al. Short communication Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques , 2003 .
[49] J. Chirgwin,et al. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.
[50] H. Hense,et al. [Descriptive epidemiology of Ewing's tumor--analysis of German patients from (EI)CESS 1980-1997]. , 1999, Klinische Padiatrie.